What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol by Vang, Ole et al.
What Is New for an Old Molecule? Systematic Review and
Recommendations on the Use of Resveratrol
Ole Vang1*, Nihal Ahmad2, Clifton A. Baile3, Joseph A. Baur4, Karen Brown5, Anna Csiszar6, Dipak K.
Das7, Dominique Delmas8, Carmem Gottfried9, Hung-Yun Lin10, Qing-Yong Ma11, Partha
Mukhopadhyay12, Namasivayam Nalini13, John M. Pezzuto14, Tristan Richard15, Yogeshwer Shukla16,
Young-Joon Surh17, Thomas Szekeres18, Tomasz Szkudelski19, Thomas Walle20, Joseph M. Wu21
1Department of Science, System and Models, Roskilde University, Roskilde, Denmark, 2Department of Dermatology, University of Wisconsin, Madison, Wisconsin, United
States of America, 3Department of Animal and Dairy Science, University of Georgia, Athens, Georgia, United States of America, 4Department of Physiology and Institute
for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 5Department of Cancer
Studies and Molecular Medicine, The Biocentre, University of Leicester, Leicester, Great Britain, United Kingdom, 6 Reynolds Oklahoma Center on Aging, University of
Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America, 7Cardiovascular Research Center, University of Connecticut School of Medicine,
Farmington, Connecticut, United States of America, 8 INSERM U866, University of Burgundy, Dijon, France, 9Department of Biochemistry, Postgraduate Programme of
Biochemistry, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, 10 Signal Transduction Laboratory, Ordway Research Institute,
Albany, New York, United States of America, 11Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China,
12 Laboratory of Physiological Studies, Section on Oxidative Stress Tissue Injury, National Institutes of Health, Rockville, Maryland, United States of America,
13Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamil Nadu, India, 14College of Pharmacy, University of Hawaii at Hilo, Hilo,
Hawaii, United States of America, 15UFR Pharmacie, University of Bordeaux, Villenave d’Ornon, France, 16 Proteomics Laboratory, Indian Institute of Toxicology Research,
Lucknow, Uttar Pradesh, India, 17College of Pharmacy, Seoul National University, Seoul, South Korea, 18Clinical Institute of Medical and Chemical Laboratory Diagnostics,
General Hospital of Vienna, Medical University of Vienna, Vienna, Austria, 19Department of Animal Physiology and Biochemistry, August Cieszkowski University of
Agriculture, Poznan, Poland, 20Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South
Carolina, United States of America, 21Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York, United States of America
Abstract
Background: Resveratrol is a natural compound suggested to have beneficial health effects. However, people are
consuming resveratrol for this reason without having the adequate scientific evidence for its effects in humans. Therefore,
scientific valid recommendations concerning the human intake of resveratrol based on available published scientific data
are necessary. Such recommendations were formulated after the Resveratrol 2010 conference, held in September 2010 in
Helsingør, Denmark.
Methodology: Literature search in databases as PubMed and ISI Web of Science in combination with manual search was
used to answer the following five questions: 1Can resveratrol be recommended in the prevention or treatment of human
diseases?; 2Are there observed ‘‘side effects’’ caused by the intake of resveratrol in humans?; 3What is the relevant dose of
resveratrol?; 4What valid data are available regarding an effect in various species of experimental animals?; 5Which relevant
(overall) mechanisms of action of resveratrol have been documented?
Conclusions/Significance: The overall conclusion is that the published evidence is not sufficiently strong to justify a
recommendation for the administration of resveratrol to humans, beyond the dose which can be obtained from dietary
sources. On the other hand, animal data are promising in prevention of various cancer types, coronary heart diseases and
diabetes which strongly indicate the need for human clinical trials. Finally, we suggest directions for future research in
resveratrol regarding its mechanism of action and its safety and toxicology in human subjects.
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Introduction
Resveratrol (Resv) is a simple molecule that has taken the
spotlight since the first scientific paper described a possible
preventive effect on cancer in mice [1]. Resveratrol occurs
naturally in low amounts in various edible plants, but the fact that
Resv is found in red wine increases its relevance as being easily
accessible to the general population. The applications of Resv
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therefore receive strong attention from the general population, the
scientific community and companies invested in food additives,
cosmetics and ‘‘natural medicine.’’
A number of long-term clinical studies in humans have recently
been initiated or is under planning and ideally in 2–5 years, we will
know much more about the biological effects of Resv in humans.
But before these data are available, the prediction of biological
effects of Resv in humans have to rely primarily on data obtained
in experimental animals and from in vitro screening in combination
with elucidation of its mechanism of action. All reliable Resv data
should be included to convert knowledge generated in animals into
a clinically safe Resv treatment approach in humans. Therefore, a
critical evaluation of the present scientific state-of-the-art knowl-
edge is needed.
The aim of the recent conference, Resveratrol2010, 1st
International Conference on Resveratrol and Health (www.resveratrol2010.
com), was to present the state-of-art of knowledge in the Resv field.
After the conference invited speakers and the scientific committee
formed a working group which formulated the recommendations
described herein.
The task of the working group discussion was to formulate a
number of scientifically based recommendations for 1the human
use of resveratrol and 2research on resveratrol for the coming
years based on scientific literature and data made available
during the previous 2K days of the conference. As Resv has been
suggested to promote health in relation to various diseases or
sufferings, the participating scientists covered a broad range of
research on the biological effects of Resv, which included the
following subjects, 1resveratrol and cancer; 2resveratrol and heart
disease; 3neuroprotective activity of resveratrol; 4effect of
resveratrol on longevity; 5effect of resveratrol on inflammation;
6effect of resveratrol on obesity and diabetes; 7metabolism and
stability of resveratrol and 8production and commercial use of
resveratrol.
The final recommendations to the use of resveratrol are given in
Tables 1, 2, 3, 4, 5, 6, whereas Table 7 describes recommenda-
tions for research goals for the coming years in this field. The
recommendations to the use of resveratrol do not differentiate
between Resv used as a drug (for disease treatment), as part of food
or as food supplement (maintenance of good health). On the other
hand, Resv consumption as a food item or food supplement is
considered as the primary area.
Methods
To generate a scientifically valid foundation for the formulation
of these recommendations, a systematic search was performed in
MEDLINE (http://www.ncbi.nlm.nih.gov/pubmed/) and ISI
Web of Science (http://apps.isiknowledge.com/) to indentify
studies in humans or experimental animals on Resv in relation
to cancer, coronary heart disease, diabetes/metabolic syndrome,
neurodegenerative diseases and inflammation up to September
2010. The search terms ‘‘resveratrol’’ was used in combination
with ‘‘cancer’’, ‘‘carcinogenesis’’, ‘‘chemoprevention’’, ‘‘hyperten-
sion’’, ‘‘heart failure’’, ‘‘myocardial infarct’’, ‘‘cardiac arrest’’,
‘‘ischemia heart disease’’, ‘‘stroke’’, ‘‘serum lipids’’, ‘‘metabolic
syndrome’’, ‘‘obesity’’, ‘‘diabetes’’, ‘‘insulin sensitivity’’, ‘‘plasma
glucose’’, ‘‘visceral fat’’, ‘‘neuroprotection’’, ‘‘neuroprotective’’,
‘‘inflammation’’ or ‘‘inflammatory’’, were used to search for words
in titles, abstracts, or Medical Subject Headings. The search was
limited to English language but include both human data and
experimental animals. Beside the database searches a manual
search was performed using reference lists of original articles and
previous reviews. For all studies, only the original publication was
included in the present evaluation. Only studies investigating Resv
and Resv metabolites are evaluated whereas various derivatives of
resveratrol were not included.
The identified publications were used to answer the following
five questions: 1Can resveratrol be recommended in the
prevention or treatment of human diseases?; 2Are there observed
side effects caused by intake of resveratrol in humans?; 3What is
the relevant dose of resveratrol?; 4What valid data are available
regarding an effect in various species of experimental animals?;
5Which relevant (overall) mechanisms of action of resveratrol have
been documented?
Results
The term ‘‘resveratrol’’ is found in title, abstract or MESH
word in 5425 or 3650 publications following searching on ISI
Web of Science or PubMed, respectively. The substantially
higher number of hits found in ISI Web of Science was due to
abstracts or papers with focus on identification of sources of Resv.
All the publications relevant for this systematic review were
present in both data bases and the refinement of the search using
PubMed is indicated in Figure 1. To identify the cancer
Table 1. Recommendations for the use of resveratrol – part 1.
Can resveratrol be recommended in the prevention or treatment of
human diseases?
N There are not yet unequivocal scientific data for the effect of resveratrol as a
disease preventative substance in humans nor for human life extension.
N There is not yet sufficient evidence for a therapeutic effect of resveratrol in
humans, either alone or in combination with other natural compounds or
formulations.
doi:10.1371/journal.pone.0019881.t001
Table 2. Recommendations for the use of resveratrol – part 2.
Are there observed ‘‘side effects’’ caused by the intake of resveratrol
in humans?
N There are no valid data on the toxicity of chronic intake of resveratrol in
humans.
N A short term human study (29 days) indicated frequent gastrointestinal
discomfort/diarrhea only at high doses (2.5 g or 5 g per day). Only minor and
inconsistent side effects have been observed in other short-term or acute
studies.
doi:10.1371/journal.pone.0019881.t002
Table 3. Recommendations for the use of resveratrol – part 3.
What is the relevant dose of resveratrol?
N A relevant or optimal dose for resveratrol has yet to be established by human
studies and will almost certainly vary depending on the effect being studied.
N Doses in the range of hundreds of mg to several g per day have been
proposed based on animal studies, but more human studies are needed to
confirm these estimates.
N Chronic human intake above the concentrations contained in natural food
should be considered experimental until long-term human studies have been
performed.
doi:10.1371/journal.pone.0019881.t003
Recommendations on the Use of Resveratrol
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preventive potential of Resv, in total 1191 papers were identified
(Figure 1A), but by excluding non English papers, reviews and
papers analyzing acute or in vitro effects only, 41 articles were
found to test Resv in animal model systems, whereas two studies
focused on the effect of Resv in human subjects. The effect of
Resv on coronary heart diseases was investigated in 118 papers
(Figure 1B); whereas only 26 papers show data from non acute
animal experiments and one paper was identified investigating
effect in humans. Focusing on the effect of Resv on obesity and
related diseases such as diabetes, 218 articles were identified
(Figure 1C), but only 19 animal studies and no human studies
focused on non-acute effects of Resv. Neuroprotection by Resv
was in focus of 163 papers (Figure 1D), but 40 papers concerned
animal studies, including both acute exposure and sub- and
chronic studies. Lastly, 559 papers focused on resveratrol and
inflammation (Figure 1E), and of these 31 papers included sub
chronic and chronic studies, whereas no human studies focusing
on inflammation have been published.
Discussion
Can resveratrol be recommended in the prevention or
treatment of human diseases?
Amajor challenge for scientists investigating Resv is to prove that
it has the health promoting effects, which have been suggested based
on the in vitro and animal studies available. Clinical trials with Resv
in human subjects focusing on the health promoting effect of Resv
are lacking. Therefore, these studies have the highest priority in
recommendations from the scientific working group (Table 7). Two
clinical trials have been recently published analyzing the effect on
biomarkers of intermediary metabolism: 2.5 g Resv/day for 29 days
was found to significantly reduce the plasma level of insulin-like
growth factor-1 and insulin-like growth factor binding protein-3
indicating a possible cancer preventive effect [2], whereas daily
doses of 0.5 and 1.0 g Resv/day for 29 days caused a reduction of
cell proliferation in colon cancer tissue [3].
Most of the available clinical studies with Resv in humans focus
on bioavailability, pharmacokinetics and metabolism of Resv
[4–11]. These studies showed that Resv was rapidly absorbed after
oral intake; a maximal plasma concentration of Resv obtained
after 30 to 60 minutes. Further, the level of Resv in the blood
Table 4. Recommendations for the use of resveratrol – part 4.
What valid data are available regarding an effect in various species of
experimental animals?
N There is sufficient evidence for a chemopreventive effect of resveratrol on the
development of cancer in skin of mice. There are promising results on the
prevention of colon cancer in animals. The effects of resveratrol on other cancer
types than skin cancer need to be investigated more in detail prior to
recommending clinical trials.
N There is sufficient evidence to suggest resveratrol reduces the incidence of
hypertension, heart failure, ischemia heart disease in experimental animal
models.
N There is sufficient evidence to suggest resveratrol improves insulin sensitivity,
reduces blood glucose levels, and reduces high fat diet-induced obesity in
rodents.
N Resveratrol showed neuroprotective effects in experimental animal models of
injury or degeneration.
N Resveratrol is well tolerated in rats and no toxicological effects are observed
up to 700–1000 mg/kg bw/day.
doi:10.1371/journal.pone.0019881.t004
Table 5. Recommendations for the use of resveratrol – part 5.
Which relevant (overall) mechanisms of action of resveratrol have
been documented?
N Modulation of cell proliferation and apoptosis
N Modulation of angiogenesis
N Inhibition of metastasis
N Modulation of redox status
N Suppression of adipogenesis and stimulation of adipocyte lipolysis
N Stimulation of osteogenesis
N Modulation of mitochondria activity
N Suppression of inflammation
N Modulation of DNA damage
N Modulation of xenobiotic metabolism
N Modulation of glutamate metabolism
N Estrogenic activity/anti-estrogenic activity
doi:10.1371/journal.pone.0019881.t005
Table 6. Overall conclusions for the use of resveratrol.
1 Published evidence today is not sufficiently strong to justify
recommendation for the chronic administration of resveratrol to human
beings, beyond the dose which can be obtained from dietary sources.
2 Animal data are promising and indicate the need for further human clinical
trials.
doi:10.1371/journal.pone.0019881.t006
Table 7. Recommendations for research on resveratrol for
the coming years.
1 Clinical studies should be initiated, especially with focus on the effect of
resveratrol on the development of cancers in colon and skin
2 Clinical studies should be initiated to test the potential cardio-vascular
benefit of resveratrol
3 Elucidating the biological effects of resveratrol metabolites
4 Biodistribution and degradation of resveratrol in vivo, including the role of
bacterial enzymes
5 Preparation of a resveratrol reference (international standard) product for
analytical purposes
6 Standardized formulations for clinical studies
7 Combinatory effects of resveratrol with other compounds. This include
development of relevant models
8 Interaction of resveratrol with drug metabolism (especially cytochrome
P450 metabolism)
9 Identification/development of relevant biomarkers, relevant for the disease-
prevention rather than disease treatment, depending on the relevant
disease
10 Effect of resveratrol on inflammation as general condition relevant for
several lifestyle diseases
11 Long term preclinical studies in nonhuman primates may be appropriate to
determine the effect of resveratrol on diet-induced metabolic disorders,
such as development of insulin resistance
doi:10.1371/journal.pone.0019881.t007
Recommendations on the Use of Resveratrol
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stream was low, likely caused by rapid metabolism to glucuronide
and sulphate conjugates. In addition to the studies described
above, levels of Resv after ingestion of Resv-containing items such
as wine or grape juice have been investigated [12–15]. However,
the specific effect of Resv is difficult to estimate when given as part
of food matrices.
Two clinical studies were described by Elliott et al., where the
effect of Resv on type 2 diabetic patients was tested at 2.5 or 5.0 g/
day for 28 days [16]. The levels of fasting and postprandial plasma
glucose and postprandial serum insulin were statistically signifi-
cantly decreased with 5.0 g/day, but the experimental details were
not given.
The tissue distribution of Resv and its metabolites was estimated
in a study where twenty colon cancer patients received 0.5 g or
1.0 g Resv daily for eight days before surgical resection [3]. The
level of Resv was found in colon tissue at a level sufficient to elicit
anticarcinogenic effects observed in in vitro tests. A recent
experiment showed that single doses of 250 and 500 mg Resv
significantly increased cerebral blood flow but the cognitive
performance was unaltered [17].
Several clinical trials of oral Resv as a pure compound or using
Resv-rich products (grapes and grape juice) are under way. In total,
24 clinical studies are listed at the homepage http://clinicaltrials.
gov/ [18] having Resv as the major experimental subject or as part
of a clinical trial. Therefore, it is our recommendation that clinical
trials should focus on biomarkers of cancers, diabetes and metabolic
syndromes as well as neurological diseases (Table 7).
Based on the limited number of human studies, the working
group has concluded that there is not at the moment enough
available and scientifically valid data on the effect of Resv to
Figure 1. Flow chart of systematic literature search. The literature search was performed to identify all relevant articles focusing on resveratrol
and chemoprevention (A), effect of resveratrol on cardio vascular disease (B), effect of resveratrol obesity and diabetes (C), neuroprotective effect of
resveratrol (D) and the anti-inflammatory effect of resveratrol (E). In all five groups, articles with non-english language, review articles and articles
showing data from in vitro experiments only are excluded. For chemopreventive effect (A), cardio vascular disease (B), obesity and diabetes (C), also
non-chronic animal studies were excluded.
doi:10.1371/journal.pone.0019881.g001
Recommendations on the Use of Resveratrol
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conclusively state whether it could be a disease preventive
substance in humans or could be used for human life extension
(Table 1). It is therefore vital to perform such studies.
Are there observed side effects caused by the intake of
resveratrol in humans?
Based on animal studies, Resv is generally well tolerated, and
only very few short-term or acute exposure experiments in humans
have been performed. When eight healthy subjects were exposed
to 2000 mg Resv twice/day for eight days, six of eight subjects had
mild episodic diarrhea/loose stool, typically in the beginning of the
eight days treatment period, and one of the subjects developed a
temporary rash and headache [9]. In a double-blinded, random-
ized, placebo-controlled study, up to 975 mg/day were given to
healthy volunteers, where two adult subjects (male and female) in
each group were subjected to 25, 50, 100 or 150 mg, six times/
day, for two days in total. Adverse effects were mild in severity and
similar between all groups. Repeated administration of Resv was
well-tolerated but produced relatively low plasma concentrations
of Resv, despite the high doses and short dosing interval used [10].
Exposure of up to 270 mg Resv to 19 volunteers for one week did
not cause any discomfort [19].
According to Elliott et al. healthy volunteers tolerated Resv well
in a seven-day exposure study, but experimental details were not
provided thus making evaluation of results challenging [16]. The
same article describes very briefly a study which included daily
exposure to 2.5 g or 5 g Resv for 28 days. The authors reported
that ‘‘Adverse events were generally mild in nature and reversible’’
but no experimental details are shown, which made a closer
evaluation impossible [16]. The 20 colon cancer patients receiving
0.5 g or 1.0 g Resv daily for eight days before surgical resection
[3] tolerated it well.
It is difficult to estimate the normal human consumption of Resv
as the intake of red wine (verified main source of Resv) differs greatly
in the population and the content of Resv varies (mean
1.961.7 mg/L) [20], but the dose may be up to 4 mg/person/day.
Only a single experiment has tested Resv in a classical chronic
exposure experiments, i.e. at least 24 months in rats or 18 months in
mice [21] and Resv does not in general cause any toxic effects in
animal studies published except at doses above 1 g/kg bw/day.
Besides acute exposure to Resv, several sub chronic experiments
have indicated low toxicity. In male Sprague-Dawley rats, 20 mg
Resv/kg bw/day given for 28 days did not indicate systemic toxicity
[22]. Oral doses of 300, 1000 or 3000 mg Resv/kg bw/day for 28
days only showed toxic effects in the 3000 mg treatment group (CD
rats, both sexes) [23], where nephropathy and renal toxicity were
observed as well as changed clinical markers of liver metabolism.
Exposure of Wistar rats to Resv (50, 150 or 500 mg/kg bw/day) for
four weeks or three months to 120, 300 or 700 mg/kg bw/day did
not show significant toxicological effects [24]. An additional study of
28 days in rats is mentioned by Elliott et al., which showed ‘‘a no
effect level’’ at 300 mg/kg bw/day [16] but no experimental details
were given and the results could not be fully evaluated. CD rats
(both sexes) exposed to 0, 300, 1000 or 3000 mg Resv/kg bw/day
by gavages for 28 days showed only mild liver toxicity as well as
nephrotoxicity when exposed to the highest dose [25]. In a study,
where female Sprague-Dawley rats were exposed to Resv (1 g/kg
diet, corresponding to about 100 mg/kg bw/day in an adult), for
the entirety of their life starting at birth showed no toxicological
signs such as reduced food intake, reduced body weight, or delayed
sexual maturation [26].
In mice (C57BL/6 p532/2) oral administration of Resv (1000,
2000, 3000, 4000 or 5000 mg/kg bw/day) showed an increased
death rate caused by impaction of Resv in the gastrointestinal tract
[27]. Long term administration of Resv in drinking water (14 mg/
L water) to mice for six months cause a reduced organ weight but
these differences were not present in a corresponding 12 month
experiment [28].
Elliott et al [16] cites a study of Resv exposure to rabbits: Severe
toxicity was observed at high doses with the kidney as the primary
target. The ‘no effect level’ was estimated at 500 mg/kg bw/day in
males and 250 mg/kg bw/day in females [16], but no further
details were given in the paper. Likewise, Elliott et al. cites a study
on the effect of Resv in dogs for 28 days, which showed no toxic
effects at 300 mg Resv/kg bw/day, but no details were given [16].
Several experiments have shown that Resv does not have
genotoxic activity, based on the Ames test [16,24], but
experimental details are too limited to evaluate the data fully.
Supporting this, there was no increase in the frequency of
micronucleated immature erythrocytes observed in rats exposed to
up to 200 mg Resv/kg bw/day [24].
Reproductive toxicity was evaluated in rats and the maternal
‘no observed adverse effect level’ (NOAEL) was estimated at
300 mg/kg bw/day and the developmental NOAEL was
estimated at 300 mg/kg bw/day, but no experimental details
were given [16]. A study described by Williams et al, indicated that
the NOAEL for maternal toxicity and embryo–fetal development
was around 750 mg Resv/kg bw/day [24]. Based on these
observations, the paper concluded that a daily dose of 450 mg was
safe for a 60 kg person, using a 10 fold safety factor [24] which is
further the basis of the self affirmed GRAS (Generally Recognized
As Safe) status up to 450 mg Resv/day from several Resv
producers.
Several examples of self reported side effects of Resv intake may
be found on various homepages from the internet, but there is no
comprehensive evaluation of these self reported side effects.
Based on the available data, which mostly originate from studies
of very short duration, the working group formulated the following
conclusions (Table 2):
N There are no valid data on the toxicity of chronic intake of
resveratrol in human subjects.
N A short term human study (29 days) indicated frequent
gastrointestinal discomfort/diarrhea only at high doses (2.5 g
or 5 g per day). Only minor and inconsistent side effects have
been observed in other short-term or acute studies.
What is the relevant dose of resveratrol?
Resveratrol has been proposed to be active in the prevention of
various life style diseases such as cancer, coronary heart diseases
and type 2 diabetes. Different mechanisms are likely involved
besides the modulation of inflammation as a unifying mechanism.
Because of different mechanisms and targets one must assume that
the optimal dose will depend on the particular disease.
As indicated above, only a few human studies have been
performed, showing down-regulation of cancer biomarkers by 2.5 g
Resv/day for 28 days [2] and reduced cell proliferation in colon
cancer tissue was observed in humans at doses of 0.5 and 1.0 g
Resv/day [3]. A single double-blind, randomized cross-over human
study focused on the effect of Resv on flow-mediated dilatation of
the brachial artery (as a biomarker of reduced endothelial function
and cardiovascular health) in overweight/obese men and women:
Resv, at sub chronic doses of 30, 90 and 270 mg/day for one week,
showed a significant dose-dependent increase in flow-mediated
dilation, significant even at the 30 mg dose [19].
Several human studies have investigated the effects of Resv
containing food items. The exposure to Resv is likely in all cases
Recommendations on the Use of Resveratrol
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less than 4 mg. Human acute or sub chronic (two weeks) intake of
red wine, dealcoholized red wine or red grape juice did not show
effect on Tumor necrosis factor (TNF) a, Interleukin (IL)-2 or IL-4
levels, indicating no anti-inflammatory response of the wine but
the presence of Resv in the wine was not proven [29,30]. Exposure
of healthy volunteers to 36 mg Resv/day (combination of trans- and
cis-Resv and cis-piceid) in the form of Chardonnay cava wine for
28 days caused a reduction of various inflammatory markers such
as IL-6, high-sensitivity C-reactive protein (CRP), intercellular
adhesion molecule-1 (ICAM-1) and monocyte chemoattractant
protein-1 (MCP-1) [31].
Resveratrol is found to reduce the risk of colon cancer
development in experimental animals (see below) using doses in
the range of 0.2 to 8 mg/kg in rats and 2.4 to 60 mg/kg in mice.
Applying the dose translations factors described by Reagan-Shaw
et al. [32] the corresponding daily ‘human equivalent doses’ (HED)
are around 2 mg–78 mg (based on rat data) or 12–290 mg (based
on mouse data) for a 60 kg person.
Enhanced insulin sensitivity by Resv was observed in experi-
mental animals when exposed to 2.5–400 mg/kg in mice and
1–100 mg/kg in rats (see below). The corresponding HED are
12–1945 mg (based on mouse data) or 10–973 mg/day for a 60 kg
person.
The relevant effective dose of Resv needs to be established in
humans in relation to the different diseases that it may counteract
and the working group concludes (Table 3) that:
N A relevant or optimal dose for resveratrol has yet to be
established by human studies and will almost certainly vary
depending on the effect being studied.
N Doses in the range of hundreds of mg to several g per day have
been proposed based on animal studies, but more human
studies are needed to confirm these estimates.
N Chronic human intake above the concentrations contained in
natural food should be considered experimental until long-
term human studies have been performed.
Which valid data is available regarding an effect in
various species of experimental animals?
Cancer preventive activity. The initial paper by Jang et al.
showed a cancer preventive effect of Resv on skin cancer in a mice
model. Seven animal studies have been identified studying the
effect of Resv on skin cancer (Table S1) all showing reduction of
the incidence of chemically induced skin cancer [1,33–36],
whereas no reduction was observed in a mouse line spontaneous
to developing polyps [37]. Only mice have been used in these
studies with different Resv concentrations, dose regimens and
exposure times (up to 28 week). A recent study supported this by
showing reduction of skin hyperplasia by Resv alone and in
synergism with other dietary components [38].
To test the effect of Resv on breast cancer, four studies used
mice where Resv showed a reducing effect in three experiments
[1,39,40] (in chemical induced cancers, in a HER-2/neu
transgenic mice model and injected Ehrlich ascites carcinoma
cells), whereas Resv failed to show chemoprevention in a model
where 4T1 mammary carcinoma cells were injected into the mice
[41]. In rats, three studies showed a chemopreventive effect of
Resv [26,42,43], whereas increased breast cancer incidence is
observed in one study [44]. The reason for these contradictory
results is not obvious.
Resveratrol reduced chemically-induced liver cancer in rats [45]
and in mice injected with carcinoma cells [46–48]. A single
experiment showed no reduction of the incidence of esophagus
carcinoma formation by Resv [49]. The effect of Resv on gastric
cancers was evaluated with its effect on tumor growth after
subcutaneous injection of cancer cells. Both studies in mice showed
a reduced tumor volume as a consequence of Resv exposure [50,51].
To study the effect of Resv on colon cancer development in
animals, four studies focus on chemically-induced colon cancer in
rats or mice [52–55] and three studies evaluated the effect of Resv
on colon cancer in APC/Min mice strains [56–58]. Three of the
tests showed significant reduction of the aberrant crypt formation
or incidence of adenomas, whereas two of the mouse studies did
not show a significant reduction in colon cancer incidence or
tumor load.
Resveratrol showed a chemopreventive effect on development
of prostate cancer using rat or mice strains prone to spontaneously
developing prostate cancer [59–61] and a mouse model with
injected prostate cancer cells [62] In other studies focusing on lung
carcinogenesis, Resv showed a chemopreventive effect only in a
single experiment out of a total of four experiments [63–66]. A
single study focused on the effect of Resv on the development of
neuroblastoma in mice, and found reduced tumor volume [67].
Cardioprotective effect of resveratrol. Risk reduction of
cardiovascular events is one of the most well-known health
promoting effects of Resv. It has been shown that Resv may
modulate various aspects of cardio-vascular diseases, including
atherosclerosis, hypertension, ischemia reperfusion injury and
heart failure.
Resveratrol reduced hypertension in various models (Table S2),
including spontaneously hypertensive rats [68,69], salt induced
hypertension [70], hypertension induced by monocrotaline
[71,72], or obesity-induced hypertension [73–76]. In nine out of
eleven studies, Resv (at levels of 10 mg/kg bw/day or higher) was
found to reduce the elevated blood pressure. The blood pressure
reducing effect of Resv was observed after 3 weeks and maintained
for 10 weeks. Low exposure to Resv (2.5 mg/kg bw/day for 10
weeks) was described in two experiments using spontaneous hyper-
tensive rat where one experiment showed a preventive effect on
hypertension whereas the other did not.
Several studies (five have been identified) showed a preventive
effect of Resv on myocardial infarction induced by surgery. All
studies showed a reduced infarct size effect and one experiment
even at the low dose of 1 mg Resv/kg bw/day for four weeks
[77–81]. Chronic treatment with Resv reduced infarct area after
middle cerebral artery occlusion [82]. The diabetes-induced
myocardial infarct size was significantly reduced by Resv (ranging
from 1 to 5 mg/kg bw/day) in rats exposed to Resv for 5–15 days
[83–85]. Further, Resv may precondition the heart in a nitric
oxide (NO)-dependent manner, which would reduce heart damage
from ischemia [85]. Resveratrol prevented the effects of ischemia
at doses of 10 mg/kg, whereas higher doses were found to depress
cardiac function and increase myocardial infarct size [86,87]. A
single experiment was performed in swine where the reduced
inferolateral function induced by hypercholesterolemic diet was
prevented by 100 mg Resv/kg bw/day [88].
Obesity and type 2 diabetes. Animal studies focusing on
the effect of Resv on obesity and diabetes are shown in Table S3.
Some studies have indicated that intake of Resv may reduce body
weight increase caused by high fat intake in mouse [89] and grey
mouse lemurs [90] both exposed to high levels of Resv (200 or
400 mg/kg bw/day). Low doses, up to 60 mg/kg bw/day did not
show any effect on body weight [21,73,76,91]. On the other hand,
low doses did affect lipid accumulation observed as reduced size of
white adipose tissue [91], reduced abdominal obesity [92],
reduced abdominal fat in obese rats [73] and reduced grade of
steatosis [93].
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The effect of Resv on insulin sensitivity has been the subject in
nine studies using rats or mice in which insulin sensitivity was
reduced by high fat diets, using animal strains prone to developing
insulin resistance or by chemically induced diabetes (treatment
with streptozotocin). Nearly all experiments showed a reduced
insulin level or increased insulin sensitivity using doses covering
2.5–400 mg/kg bw/day and exposure time covering 1–6 months
[21,73,89,92,94,95]. One study, using AMPKa12/2 and wild-type
C57BL/6J mice fed a high-fat diet and exposed to 400 mg Resv/
kg bw/day for 12 weeks found an effect of Resv on insulin
sensitivity in wild-type, but not AMPKa12/2 mice [96]. In
C57BL/6 male mice fed a high-calorie diet and a low dose of Resv
(79.2 ng/day, infused intra-cerebro ventricularly) for five weeks,
reduced the serum insulin levels significantly [97], indicating that
the active dose of Resv for prevention of elevated insulin levels is
low and may be mediated the central nervous system.
Ten studies have been identified which investigated the effect of
Resv on blood glucose levels, using genetically obese mice or rats,
dietary induced obesity or chemically induced diabetes by STZ or
alloxan [21,73,83,85,94,97–101]. Only one study [101], per-
formed on rabbits with alloxan-induced diabetes, didn’t find a
reduced blood glucose level following exposure to Resv for 5 days
to 2 months.
Neuroprotective action of resveratrol. Several animal
studies have indicated that Resv has a neuroprotective effect
(Table S4). In total, 12 studies test the effect of resveratrol after a
single exposure and 28 studies investigated the effect of resveratrol
af subchronic/chronic exposure. This effect of Resv has been
documented in various animal models including rabbits [102],
mice or rats and using different end points, such as reduced lipid
peroxidation and neurological cell destruction [100,103–107],
attenuation of induced lesion areas [82,108–115], induced
tolerance to brain injury [116], reduced frequency of seizures
[117], impairment of motor coordination [102,104,118–124] and
enhancement of learning [125–127]. Only very few of these
experiments found no or a marginal effect of Resv. A significant
number of these studies use acute doses of Resv, ranging 5–
100 mg/kg using one dose or exposure to the animals for Resv up
to 1 week. Thirteen studies unraveling the neuroprotective effect of
Resv expose to the experimental animals for more than 3 weeks:
10–50 mg Resv/kg bw/day for 3–6 weeks [100,104,105,
126,128,129], 100–300 mg Resv/kg bw/day for 3–6 weeks
[107,111,122], 10–40 mg/kg bw/day for 10 weeks [130], or
three weeks exposure of 2.5 mg Resv (by intra-cerebroventricular
injection) every 2–3 day for 3 weeks [125].
Modulation of inflammation by resveratrol. Inflammatory
response is a well known mechanism of the diseases described above
such as cancer, coronary-heart disease, diabetes and
neurodegeneration. Resveratrol is shown to modulate the
inflammatory response induced by various stimuli. Fourteen
studies have investigated the effect of exposure of one week or
more to Resv on various inflammatory markers in rats. The same
number of studies has been identified using mice as an experimental
model. Generally, Resv in nearly all models counteracted the
increased levels of pro inflammatory biochemical markers, such as
TNFa, IL-1b, IL-6 in nearly all models. Beside these cytokines,
MCP-1, COX-2 and iNOS was most often found to be down-
regulated by Resv when stimulated by the pro-inflammatory
treatment. The estimates of inflammation were often performed
as a part of a study with another aim, i.e. testing a chemopreventive
effect, or the effect of Resv on diabetes or cardiovascular disease.
Therefore, different inducers of the inflammatory status have been
used; Resv reduced inflammation in several models such as obesity-
induced [73], in diabetic mice [131] or chemically induced diabetes
[124,132,133], but also dextran sulfate sodium induced colon colitis
[55,134–138]. Other models were using induced hypertension
[72,139], chemicals causing tissue injury (and act as carcinogen) in
liver [140], lung [141,142] and colon [143–145] and showed
decreased levels of inflammatory markers (Table S5).
Besides the animal experiments described above which focused
on chronic or near-chronic exposures, a long list of papers exist that
analyze the effect of Resv after an acute exposure on biomarkers
relevant for prevention of cancer, coronary-heart disease and
diabetes. These articles are not included in the present review.
The working group concluded (Table 4):
N There is sufficient evidence for a chemopreventive effect of
resveratrol on the development of skin cancer in mice. There
are promising results on the prevention of colon cancer in
animals. The effects of resveratrol on other cancer types
besides skin cancer need to be investigated more in detail prior
to recommending clinical trials.
N There is sufficient evidence to suggest that resveratrol reduces
the incidence of hypertension, heart failure, ischemia heart
disease in experimental animal models.
N There is sufficient evidence to suggest that resveratrol improves
insulin sensitivity, reduces blood glucose levels, and reduces
high fat diet-induced obesity in rodents.
N Resveratrol showed neuroprotective effects in experimental
animal models of injury or degeneration.
N Resveratrol is well tolerated in rats and no toxicological effects
are observed up to 700–1000 mg/kg bw/day.
Which relevant (overall) mechanisms of action of
resveratrol have been documented?
Without going too much into details, and without giving the
references, several mechanisms of action of Resv are relevant in
relation to its proposed enhancement of human health. A number
of mechanisms are relevant for several of the diseases mentioned
herein, whereas others are more specific. The working group has
identified twelve such mechanisms, as listed in Table 5. They are
closely related and it is not possible to focus solely on one
mechanism without taking the other mechanisms into consider-
ation. Further, the indicated mechanisms are identified in in vitro,
in experimental animals or both.
Suppression of inflammation is a general mechanism relevant
for prevention of cancer diseases, coronary heart diseases, diabetes
and neurodegeneration, as indicated above. Similarly, modulation
of the cellular redox status is closely related to several diseases and
linked to the anti-inflammatory effect. Modulation of cell
proliferation and apoptosis as well as modulation of angiogenesis,
inhibition of metastasis and suppression of DNA damage are
relevant especially in cancer diseases. Modulation of xenobiotic
metabolism by Resv likely plays a significant role in cancer
prevention but may also have an impact on metabolism of drugs
used to treat the listed diseases. Modulation of mitochondrial
activity seems crucial in obesity/diabetes but may also be relevant
for understanding life extension as well as be related to the
inhibition of cell proliferation. Suppression of adipogenesis and
stimulation of adipocyte lipolysis by Resv is relevant when one
consider the effect on obesity and diabetes. Relevant for
neuroprotection by Resv is the modulation of glutamate
metabolism. Resveratrol also stimulates osteogenesis which
indicates an effect on bone biology. Estrogenic activity but also
anti-estrogenic activity by Resv has been shown but the clinical
significance of these observations is uncertain.
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Recommendations on relevant research to be performed
in the near future
It clearly follows from the recommendations for the use of Resv
that evidence for the effect of Resv in humans is lacking. Table 7
shows the research in the field of Resv considered of highest
priority. These recommendations naturally do not give space for
a full list of relevant research projects, but only the most relevant
from the point of view of the scientific working group of the
Resveratrol2010 conference. The clinical studies with focus on
cancer prevention might have a high priority, and as the most
clear results have been shown in animal models of cancer in skin
and colon these targets are the most relevant points of initiation.
Furthermore, investigation of the effect of Resv on metabolic
disorders evaluated in preclinical studies in nonhuman primates
also has a high priority. Relevant clinical studies should be done
soon and address the preventive effect of Resv on coronary heart
disease. However, long term studies in animal models are still
needed in order to evaluate the chronic effect of Resv to identify
a probable NOAEL in human. Since chronic low grade
inflammation is reduced by resveratrol and is a general
characteristic of several of the life style disease, the effect of
Resv on inflammatory biomarkers should be investigated in the
coming clinical studies.
One of the major challenges in the clinical studies investigating
the preventive effect of e.g. Resv is to show the absence or
reduced incidence of a specific disease end point. Such
intervention studies should then be long term and will therefore
be very expensive. To overcome these challenges, new biomark-
ers need to be identified, developed and verified to analyze the
long term disease prevention (Table 7).
To make preclinical and clinical studies comparable, the
working group suggests that a standard Resv formulation should
be performed. Such standardized Resv formulation should be
made based on very pure Resv preparations. The use of non-pure
Resv samples for preclinical or clinical experiments makes their
interpretation very difficult. On the other hand, elucidation of the
combined effect of Resv together with other dietary or non-
dietary compounds should be accelerated as combinatory effects
may solve some of the possible draw backs of high doses of
resveratrol.
Besides using a standardized Resv formulation for the pre-
clinical and clinical studies a Resv reference should be prepared
for analytical purposes, such as analyzing metabolite formation
and in the investigation of the bioavailability of Resv.
The bioavailability of Resv is described to some extent but have
to be analyzed further to find the biodistribution and the
degradation in vivo, which is very relevant to forecast the biological
effect of Resv in humans. Several Resv metabolites have been
identified but the biological activity of these metabolites formed in
humans and experimental animals needs to be elucidated fully.
Lastly, the combinatory effect of Resv with other bioactive
compounds has only been studied in few cases in experimental
animals or in vitro. These studies should be amplified, as the
outcomes of the combinations are not only additive but also
synergistic or even antagonistic. The effect of Resv on the
metabolism of these compounds have to be addressed as well, e.g.
regulation of Cytochrome P450 enzymes and activities.
Conclusions
The scientific literature cannot yet justify recommendation for
the chronic administration of resveratrol to human beings, as
stated in Table 6. Humans are receiving resveratrol frequently in
red wine, berries, peanuts etc. but these levels are low, less than
4 mg. Before having data from chronic exposure to higher levels of
resveratrol or more chronic studies with experimental animals,
intake of resveratrol at higher doses should be considered
experimental.
In contrast to the lacking data of resveratrol in humans, the
animal data are promising and indicate the need for further
human clinical trials. Therefore, the working group from the
Resveratrol 2010 conference recommends that these human trials
will be initiated soon.
Supporting Information
Table S1 Overview of the effect of resveratrol on cancer
development in experimental animals. To identify papers
investigating the cancer preventive potential of resveratrol, a
literature search using the terms ‘‘resveratrol’’ in combination with
‘‘cancer’’, ‘‘carcinogenesis’’ or ‘‘chemoprevention’’ up to Septem-
ber 2010 was performed. In total, 1191 papers were identified, but
only 41 papers were found to investigate the effect of resveratrol in
animal model systems.
(DOCX)
Table S2 Overview of the effect of resveratrol on
coronary heart disease models in experimental animals.
To identify papers investigating the effect of resveratrol on
coronary heart diseases, a literature search using the terms
‘‘resveratrol’’ in combination with ‘‘hypertension’’, ‘‘heart failure’’,
‘‘myocardial infarct’’, ‘‘cardiac arrest’’, ‘‘ischemia heart disease’’,
‘‘stroke’’ or ‘‘serum lipids’’ up to September 2010 was done. 118
papers were found, but only 26 papers showed data from non
acute animal experiments.
(DOCX)
Table S3 Overview of experiments focusing on the
effect of resveratrol on obesity and diabetes in experi-
mental animals. In total, 218 articles were identified, but only
19 animal studies were found to investigate the non-acute effects of
resveratrol. The search terms ‘‘resveratrol’’ were used in
combination with ‘‘metabolic syndrome’’, ‘‘obesity’’, ‘‘diabetes’’,
‘‘insulin sensitivity’’, ‘‘plasma glucose’’ or ‘‘visceral fat’’ in a
literature search including papers published up to September
2010.
(DOCX)
Table S4 Overview of the neuroprotective effect by
resveratrol was in focus of 163 papers, of which 40
papers concerned animal with acute exposure and sub-
and chronic exposure. The search terms ‘‘resveratrol’’ was
used in combination with ‘‘neuroprotection’’ or ‘‘neuroprotective’’
including papers published up to September 2010.
(DOCX)
Table S5 Overview of the effect of resveratrol on
inflammatory markers in experimental animals. To
identify papers investigating the effect of resveratrol on inflam-
matory markers, a literature search using the terms ‘‘resveratrol’’
in combination with ‘‘inflammation’’ or ‘‘inflammatory’’ was
done, including papers published up to September 2010. In total,
559 papers were identified, whereas only 31 papers included sub-
chronic and chronic exposures of resveratrol to experimental
animals.
(DOCX)
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